Efficacy and tolerability of cyclobenzaprine extended release for acute muscle spasm: A pooled analysis

Postgraduate Medicine

Volumn 122, Issue 4, 2010, Pages 158-169

  Weil, Arnold J ^a   Ruoff, Gary E ^b   Nalamachu, Srinivas ^c   Altman, Charles A ^d   Xie, Fang ^d   Taylor, Donald R ^e  

^a Non Surgical Orthopaedics PC   (United States)

^b Westside Family Medical Center   (United States)

^c Rehabilitation Research   (United States)

^d CEPHALON INC   (United States)

^e Comprehensive Pain Care PC ^*  (United States)

Author keywords

Acute; Cyclobenzaprine; Low back pain; Muscle spasm; Neck pain; Skeletal muscle relaxant

Indexed keywords

CYCLOBENZAPRINE; PLACEBO; AMITRIPTYLINE; CENTRAL MUSCLE RELAXANT; DRUG DERIVATIVE;

ADULT; AGED; ARTICLE; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; DISEASE ASSOCIATION; DIZZINESS; DOUBLE BLIND PROCEDURE; DROWSINESS; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPEPSIA; FATIGUE; FEMALE; HUMAN; LOW BACK PAIN; MAJOR CLINICAL STUDY; MALE; MUSCLE SPASM; NAUSEA; NECK PAIN; PATIENT COMPLIANCE; RANDOMIZED CONTROLLED TRIAL; SOMNOLENCE; TREATMENT DURATION; TREATMENT RESPONSE; XEROSTOMIA; ACUTE DISEASE; ADOLESCENT; CHI SQUARE DISTRIBUTION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DELAYED RELEASE FORMULATION; MIDDLE AGED; MULTICENTER STUDY; NONPARAMETRIC TEST; PAIN ASSESSMENT; TREATMENT OUTCOME; UNITED STATES;

ACUTE DISEASE; ADOLESCENT; ADULT; AGED; AMITRIPTYLINE; CHI-SQUARE DISTRIBUTION; DELAYED-ACTION PREPARATIONS; DOUBLE-BLIND METHOD; HUMANS; MIDDLE AGED; MUSCLE RELAXANTS, CENTRAL; PAIN MEASUREMENT; PLACEBOS; SPASM; STATISTICS, NONPARAMETRIC; TREATMENT OUTCOME; UNITED STATES;

EID: 77956629456     PISSN: 00325481     EISSN: 19419260     Source Type: Journal    
DOI: 10.3810/pgm.2010.07.2182     Document Type: Article

References (51)

1. van Tulder MW, Touray T, Furlan AD, Solway S, Bouter LM. Muscle relaxants for non-specific low back pain. Cochrane Database Syst Rev. 2003;2:CD004252.
2. Borenstein DG, Korn S. Efficacy of a low-dose regimen of cyclobenzaprine hydrochloride in acute skeletal muscle spasm: results of two placebo-controlled trials. Clin Ther. 2003;25(4):1056-1073.
3. Browning R, Jackson JL, O'Malley PG. Cyclobenzaprine and back pain: a meta-analysis. Arch Intern Med. 2001;161(13):1613-1620.
4. Andersson GB. Epidemiological features of chronic low-back pain. Lancet. 1999;354(9178):581-585.
5. Côté P, Cassidy JD, Carroll L. The Saskatchewan Health and Back Pain Survey: the prevalence of neck pain and related disability in Saskatchewan adults. Spine (Phila Pa 1976). 1998;23(15):1689-1698.
6. Sternbach RA. Survey of pain in the United States: the Nuprin Pain Report. Clin J Pain. 1986;2(1):49-53.
7. Lawrence RC, Felson DT, Helmick CG, et al; National Arthritis Data Workgroup. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part II. Arthritis Rheum. 2008;58(1):26-35.
8. Hart LG, Deyo RA, Cherkin DC. Physician office visits for low back pain. Frequency, clinical evaluation, and treatment patterns from a U.S. national survey. Spine (Phila Pa 1976). 1995;20(1):11-19.
9. Henschke N, Maher CG, Refshauge KM, Das A, McAuley JH. Low back pain research priorities: a survey of primary care practitioners. BMC Fam Pract. 2007;8:40.
10. Pai S, Sundaram LJ. Low back pain: an economic assessment in the United States. Orthop Clin North Am. 2004;35(1):1-5.
11. Maetzel A, Li L. The economic burden of low back pain: a review of studies published between 1996 and 2001. Best Pract Res Clin Rheumatol. 2002;16(1):23-30.
12. Verbrugge LM, Patrick DL. Seven chronic conditions: their impact on US adults' activity levels and use of medical services. Am J Public Health. 1995;85(2):173-182.
13. Waddell G. The clinical course of low back pain. The Back Pain Revolution. Edinburgh, UK: Churchill Livingstone; 1998:103-117.
14. Deyo RA, Mirza SK, Martin BI. Back pain prevalence and visit rates: estimates from U.S. national surveys, 2002. Spine. 2006;31(23): 2724-2727.
15. Cherkin DC, Sherman KJ, Deyo RA, Shekelle PG. A review of the evidence for the effectiveness, safety, and cost of acupuncture, massage therapy, and spinal manipulation for back pain. Ann Intern Med. 2003;138(11):898-906.
16. Chou R, Qaseem A, Snow V, et al. Diagnosis and treatment of low back pain: a joint clinical practice guideline from the American College of Physicians and the American Pain Society. Ann Intern Med. 2007;147(7):478-491.
17. Nibbelink DW, Strickland SC, McLean LF, Gould AL. Cyclobenzaprine, diazepam and placebo in the treatment of skeletal muscle spasm of local origin. Clin Ther. 1978;1(6):409-424.
18. Brown BR Jr, Womble J. Cyclobenzaprine in intractable pain syndromes with muscle spasm. JAMA. 1978;240(11):1151-1152.
19. Baratta RR. A double-blind study of cyclobenzaprine and placebo in the treatment of acute musculoskeletal conditions of the low back. Curr Ther Res Clin Exp. 1982;32(5):646-652.
20. Bercel NA. Cyclobenzaprine in the treatment of skeletal muscle spasm in osteoarthritis of the cervical and lumbar spine. Curr Ther Res. 1977;22(4):462-468.
21. Aiken DW. A comparative study of the effects of cyclobenzaprine, diazepam and placebo in the treatment of acute musculoskeletal conditions of the low back. Clinical Evaluation of Flexeril (Cyclobenzaprine HCl/MSD). Minneapolis, MN: Postgraduate Medicine Communications; 1978:34-38.
22. Bianchi M. Evaluation of cyclobenzaprine for skeletal muscle spasm of local origin. Clinical Evaluation of Flexeril (Cyclobenzaprine HCl/ MSD). Minneapolis, MN: Postgraduate Medicine Communications; 1978:25-29.
23. Scheiner JJ. Cyclobenzaprine in the treatment of local muscle spasm. Clinical Evaluation of Flexeril (Cyclobenzaprine HCl/ MSD). Minneapolis, MN: Postgraduate Medicine Communications; 1978:39-48.
24. Aiken DW. Cyclobenzaprine in the treatment of acute skeletal muscle spasm of local origin. Clinical Evaluation of Flexeril (Cyclobenzaprine HCl/MSD). Minneapolis, MN: Postgraduate Medicine Communications; 1978:30-33.
25. Steingard PM, Schilberg WL, Peterson KD. Multiclinic study of a muscle relaxant for treatment of acute musculoskeletal disorders. Osteopath Ann. 1980;8(10):44-58.
26. Katz WA, Dube J. Cyclobenzaprine in the treatment of acute muscle spasm: review of a decade of clinical experience. Clin Ther. 1988;10(2):216-228.
27. Nibbelink DW, Strickland SC. Cyclobenzaprine (Flexeril™): report of a postmarketing surveillance program. Curr Ther Res. 1980;28(6): 894-903.
28. Nichols-English G, Poirier S. Optimizing adherence to pharmaceutical care plans. J Am Pharm Assoc (Wash). 2000;40(4):475-485.
29. Greenberg RN. Overview of patient compliance with medication dosing: a literature review. Clin Ther. 1984;6(5):592-599.
30. Osterberg L, Blaschke T. Adherence to medication. N Engl J Med. 2005;353(5):487-497.
31. Darwish M, Chang S, Hellriegel ET. A pharmacokinetic comparison of single doses of once-daily cyclobenzaprine extended-release 15 mg and 30 mg: a randomized, double-blind, two-period crossover study in healthy volunteers. Clin Ther. 2009;31(1):108-114.
32. Darwish M, Xie F. Effect of food on the pharmacokinetics of once-daily cyclobenzaprine extended-release 30 mg: a randomized, open-label, crossover, single-centre study. Clin Drug Investig. 2009;29(3): 145-152.
33. Darwish M, Xie F. Comparison of the single-dose pharmacokinetics of once-daily cyclobenzaprine extended-release 30 mg and cyclobenzaprine immediate-release 10 mg three times daily in the elderly: a randomized, open-label, crossover study. Drugs Aging. 2009;26(2): 95-101.
34. Darwish M, Hellriegel ET, Xie F. Single-dose pharmacokinetics of once-daily cyclobenzaprine extended release 30 mg versus cyclobenzaprine immediate release 10 mg three times daily in healthy young adults: a randomized, open-label, two-period crossover, single-centre study. Clin Drug Investig. 2008;28(12):793-801.
35. Weil AJ. Cyclobenzaprine extended release for acute low back and neck pain. Therapy. 2009;6:871-881.
36. Malanga GA, Ruoff GE, Weil AJ, Altman CA, Xie F, Borenstein DG. Cyclobenzaprine ER for muscle spasm associated with low back and neck pain: two randomized, double-blind, placebo-controlled studies of identical design. Curr Med Res Opin. 2009;25(5):1179-1196.
37. World Medical Association. Declaration of Helsinki: ethical principles for medical research involving human subjects. http://www.wma.net/e/policy/pdf/17c.pdf. Accessed August 4, 2009.
38. International Conference on Harmonisation Working Group. ICH Harmonised Tripartite Guideline: Guideline for Good Clinical Practice E6 (R1). Presented at: International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use; Washington, DC: June 10, 1996.
39. Rollings HE, Glassman JM, Soyka JP. Management of acute musculoskeletal conditions. Thoracolumbar strain or sprain: a double-blind evaluation comparing the efficacy and safety of carisoprodol with cyclobenzaprine hydrochloride. Curr Ther Res. 1983;34(6): 917-928.
40. McHorney CA, Ware JE Jr, Lu JF, Sherbourne CD. The MOS 36-item Short-Form Health Survey (SF-36): III. Tests of data quality, scaling assumptions, and reliability across diverse patient groups. Med Care. 1994;32(1):40-66.
41. Michel A, Kohlmann T, Raspe H. The association between clinical findings on physical examination and self-reported severity in back pain. Results of a population-based study. Spine (Phila Pa 1976). 1997;22(3):296-303.
42. Grossman SA, Sheidler VR, Swedeen K, Mucenski J, Piantadosi S. Correlation of patient and caregiver ratings of cancer pain. J Pain Symptom Manage. 1991;6(2):53-57.
43. McCombe PF, Fairbank JC, Cockersole BC, Pynsent PB. 1989 Volvo Award in clinical sciences. Reproducibility of physical signs in low-back pain. Spine (Phila Pa 1976). 1989;14(9):908-918.
44. Potter NA, Rothstein JM. Intertester reliability for selected clinical tests of the sacroiliac joint. Phys Ther. 1985;65(11):1671-1675.
45. Waddell G, Main CJ, Morris EW, et al. Normality and reliability in the clinical assessment of backache. Br Med J (Clin Res Ed). 1982;284(6328):1519-1523.
46. Claxton AJ, Cramer J, Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin Ther. 2001;23(8):1296-1310.
47. Wright EC. Non-compliance-or how many aunts has Matilda? Lancet. 1993;342(8876):909-913.
48. Eisen SA, Miller DK, Woodward RS, Spitznagel E, Przybeck TR. The effect of prescribed daily dose frequency on patient medication compliance. Arch Intern Med. 1990;150(9):1881-1884.
49. Eurand Web site. Technology: Diffucaps®. http://www.eurand.com/tech_diffucaps.html. Accessed August 19, 2009.
50. Bosworth T. Special report: the proper use of muscle relaxants in musculoskeletal pain management. Prim Care Spec Ed. 2002;6:1-8.
51. Cady R, Farmer K, Schreiber C. Skeletal muscle relaxants: a new rationale for choice. Prim Care Spec Ed. 2003;7:1-4.